<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566773</url>
  </required_header>
  <id_info>
    <org_study_id>PT001003</org_study_id>
    <nct_id>NCT01566773</nct_id>
  </id_info>
  <brief_title>PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD</brief_title>
  <official_title>A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (14 Days), Four Period, Eight Treatment, Placebo-Controlled, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Six Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide, Open Label) as An Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to determine an optimal dose and dosing regimen of
      PT001 MDI for further evaluation in later stage studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess efficacy relative to placebo of GP MDI in
      subjects with moderate to severe chronic obstructive pulmonary disease (COPD) within the
      range of doses evaluated in this protocol. To this end, each dose of GP MDI will be compared
      to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12</measure>
    <time_frame>Day 14 (-1 hr, -30 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 10 hr, 11.5 hr, 12 hr)</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) normalized area under the curve 0-12 hours (AUC0-12) following chronic dosing for 14 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Highest value of FEV1 post dose on day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1</measure>
    <time_frame>Day 1 (15 min, 30 min, 1 hr, 2 hrs, no onset within 2 hrs)</time_frame>
    <description>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving at Least 12% Improvement in FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of subjects achieving at least 12% improvement in FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in Inspiratory Capacity (IC)</measure>
    <time_frame>Day 1 (1 hr and 2 hr post-dose )</time_frame>
    <description>Peak change in Inspiratory Capacity (IC) mean of 1 and 2 hour post-dose assessments minus the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1</measure>
    <time_frame>Day 7 (average of the 60 and 30-minute pre-dose values on Treatment Day 7 minus the baseline)</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1 (average of the 60 and 30-minute pre-dose values on Treatment Day 7 minus the baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from baseline in FEV1 (defined as the change at the highest value of FEV1 post-dose minus the baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough Inspiratory Capacity (IC)</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in morning pre-dose trough IC (average of the 60 and 30-minute pre-dose assessments minus the baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC</measure>
    <time_frame>Day 7 (mean of 1 hr and 2 hr post-dose assessments)</time_frame>
    <description>Peak change from baseline in IC (mean of 1 hr and 2 hr post-dose assessments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Morning Pre-dose Daily PEFR</measure>
    <time_frame>Day 7 (60 minutes pre-dose, 30 minutes pre-dose)</time_frame>
    <description>Change from baseline in mean morning pre-dose daily PEFR (peak expiratory flow rate) taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (excluding reading taken pre-dose on Visit 2 [Treatment Day 1])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Post-dose Daily PEFR</measure>
    <time_frame>Day 7 (30 minutes post-dose)</time_frame>
    <description>Change from baseline in morning post-dose daily PEFR (peak expiratory flow rate) taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (excluding reading taken pre-dose on Visit 2 [Treatment Day 1])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Evening Pre-dose PEFR</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in mean evening pre-dose daily peak flow readings taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (subjects taking Spiriva performed a single evening assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Evening Post-dose PEFR</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in mean evening post-dose daily peak flow readings taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (subjects taking Spiriva performed a single evening assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication</measure>
    <time_frame>Day 7</time_frame>
    <description>Mean number of puffs of rescue medication recorded in subject diaries during each treatment period and by treatment and numbers of days treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1</measure>
    <time_frame>Day 14 (average of the 60 and 30-minute pre-dose values on Treatment Day 14 minus the baseline)</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1 (average of the 60 and 30-minute pre-dose values on Treatment Day 14 minus the baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1</measure>
    <time_frame>Day 14</time_frame>
    <description>Peak change from baseline in FEV1 (defined as the change at the highest value of FEV1 post-dose minus the baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Mean Morning Pre-dose Trough IC</measure>
    <time_frame>Day 14 (average of the 60 and 30-minute pre-dose assessments minus the baseline)</time_frame>
    <description>Change from baseline for mean morning pre-dose trough IC (average of the 60 and 30-minute pre-dose assessments minus the baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC</measure>
    <time_frame>Day 14 (mean of 1 and 2 hour post-dose assessments minus the baseline)</time_frame>
    <description>Peak change from baseline in IC (mean of 1 and 2 hour post-dose assessments minus the baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-hour Post-dose Trough FEV1</measure>
    <time_frame>Day 14 (Baseline, 11.5 and 12 hours post dose)</time_frame>
    <description>12-hour post-dose trough FEV1 was defined as the mean of the FEV1 assessments taken at 11.5 and 12 hours post-dose minus the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Morning Pre-dose Daily PEFR</measure>
    <time_frame>Baseline, Treatment Day 1 and every day, to the end of the 14-Day Treatment period before dosing, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7)</time_frame>
    <description>Change from baseline in mean morning pre-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (mean reading excluded reading taken pre-dose on Visit 2 [Treatment 1 Day 1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Morning Post-dose Daily PEFR</measure>
    <time_frame>Baseline, Treatment Day 1 and every day, to the end of the 14-Day Treatment period 30 minutes post dosing, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7)</time_frame>
    <description>Change from baseline in mean morning post-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (mean reading excluded reading taken pre-dose on Visit 2 [Treatment 1 Day 1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Evening Pre-dose Daily PEFR</measure>
    <time_frame>Treatment Day 1 to the end of the 14-Day Treatment, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7)</time_frame>
    <description>Change from baseline in mean evening pre-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (subjects taking Spiriva performed a single evening assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Evening Post-dose Daily PEFR</measure>
    <time_frame>Through the end of the 14-Day Treatment</time_frame>
    <description>Change from baseline in mean evening post-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (subjects taking Spiriva performed a single evening assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication (End of Treatment)</measure>
    <time_frame>Day 14 (End of treatment)</time_frame>
    <description>Mean number of puffs of rescue medication recorded in subject diaries during each treatment period and by treatment and numbers of days treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 (mL) Averaging Treatment Day 7 and Day 14</measure>
    <time_frame>Day 1 through Day 14</time_frame>
    <description>Change from Baseline in Morning Pre-dose Trough FEV1 (mL) Averaging Treatment Day 7 and Day 14</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva® Handihaler® (Tiotropium Bromide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 MDI</intervention_name>
    <description>Administered as two puffs BID for 14 days</description>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 5)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI</description>
    <arm_group_label>Spiriva® Handihaler® (Tiotropium Bromide)</arm_group_label>
    <other_name>Spiriva® Handihaler®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 Placebo MDI</intervention_name>
    <arm_group_label>PT001 Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4161&amp;filename=protocol-pt001003_FINAL_Redacted.pdf</url>
    <description>protocol-pt001003_FINAL_Redacted</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <results_first_submitted>May 12, 2017</results_first_submitted>
  <results_first_submitted_qc>October 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2017</results_first_posted>
  <disposition_first_submitted>October 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 14, 2013</disposition_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 10 sites in the US from April 2012 to August 2012. Study participation maximum of 26 weeks.</recruitment_details>
      <pre_assignment_details>A randomized, double-blind,chronic dosing, four-period, eight-treatment, placebo-controlled, incomplete block, crossover, multicenter study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 18 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 9 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 4.6 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 2.4 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 1.2 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 0.6 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Spiriva® Handihaler®</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) Population: Subjects who randomized and received at least 1 dose of study drug, and had both baseline and post-baseline efficacy data for that treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All Subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-12</title>
        <description>Forced expiratory volume in 1 second (FEV1) normalized area under the curve 0-12 hours (AUC0-12) following chronic dosing for 14 days.</description>
        <time_frame>Day 14 (-1 hr, -30 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 10 hr, 11.5 hr, 12 hr)</time_frame>
        <population>MITT (Modified Intent to Treat) Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-12</title>
          <description>Forced expiratory volume in 1 second (FEV1) normalized area under the curve 0-12 hours (AUC0-12) following chronic dosing for 14 days.</description>
          <population>MITT (Modified Intent to Treat) Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="52"/>
                <count group_id="O8" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.448" lower_limit="1.405" upper_limit="1.491"/>
                    <measurement group_id="O2" value="1.416" lower_limit="1.374" upper_limit="1.459"/>
                    <measurement group_id="O3" value="1.432" lower_limit="1.389" upper_limit="1.474"/>
                    <measurement group_id="O4" value="1.416" lower_limit="1.374" upper_limit="1.458"/>
                    <measurement group_id="O5" value="1.386" lower_limit="1.342" upper_limit="1.430"/>
                    <measurement group_id="O6" value="1.353" lower_limit="1.309" upper_limit="1.397"/>
                    <measurement group_id="O7" value="1.290" lower_limit="1.246" upper_limit="1.335"/>
                    <measurement group_id="O8" value="1.514" lower_limit="1.471" upper_limit="1.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1</title>
        <description>Highest value of FEV1 post dose on day 1</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1</title>
          <description>Highest value of FEV1 post dose on day 1</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" lower_limit="191" upper_limit="272"/>
                    <measurement group_id="O2" value="226" lower_limit="186" upper_limit="267"/>
                    <measurement group_id="O3" value="165" lower_limit="125" upper_limit="205"/>
                    <measurement group_id="O4" value="170" lower_limit="130" upper_limit="211"/>
                    <measurement group_id="O5" value="136" lower_limit="95" upper_limit="177"/>
                    <measurement group_id="O6" value="107" lower_limit="65" upper_limit="149"/>
                    <measurement group_id="O7" value="57" lower_limit="17" upper_limit="97"/>
                    <measurement group_id="O8" value="270" lower_limit="229" upper_limit="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1</title>
        <description>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1.</description>
        <time_frame>Day 1 (15 min, 30 min, 1 hr, 2 hrs, no onset within 2 hrs)</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1</title>
          <description>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1.</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No onset within 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="59"/>
                    <measurement group_id="O7" value="78"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving at Least 12% Improvement in FEV1</title>
        <description>Percentage of subjects achieving at least 12% improvement in FEV1.</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving at Least 12% Improvement in FEV1</title>
          <description>Percentage of subjects achieving at least 12% improvement in FEV1.</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in Inspiratory Capacity (IC)</title>
        <description>Peak change in Inspiratory Capacity (IC) mean of 1 and 2 hour post-dose assessments minus the baseline</description>
        <time_frame>Day 1 (1 hr and 2 hr post-dose )</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in Inspiratory Capacity (IC)</title>
          <description>Peak change in Inspiratory Capacity (IC) mean of 1 and 2 hour post-dose assessments minus the baseline</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" lower_limit="163" upper_limit="304"/>
                    <measurement group_id="O2" value="263" lower_limit="193" upper_limit="333"/>
                    <measurement group_id="O3" value="151" lower_limit="82" upper_limit="219"/>
                    <measurement group_id="O4" value="183" lower_limit="113" upper_limit="252"/>
                    <measurement group_id="O5" value="126" lower_limit="54" upper_limit="198"/>
                    <measurement group_id="O6" value="82" lower_limit="9" upper_limit="155"/>
                    <measurement group_id="O7" value="80" lower_limit="10" upper_limit="150"/>
                    <measurement group_id="O8" value="343" lower_limit="271" upper_limit="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
        <description>Change from baseline in morning pre-dose trough FEV1 (average of the 60 and 30-minute pre-dose values on Treatment Day 7 minus the baseline)</description>
        <time_frame>Day 7 (average of the 60 and 30-minute pre-dose values on Treatment Day 7 minus the baseline)</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
          <description>Change from baseline in morning pre-dose trough FEV1 (average of the 60 and 30-minute pre-dose values on Treatment Day 7 minus the baseline)</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="48" upper_limit="128"/>
                    <measurement group_id="O2" value="90" lower_limit="50" upper_limit="129"/>
                    <measurement group_id="O3" value="109" lower_limit="70" upper_limit="149"/>
                    <measurement group_id="O4" value="96" lower_limit="57" upper_limit="135"/>
                    <measurement group_id="O5" value="43" lower_limit="2" upper_limit="84"/>
                    <measurement group_id="O6" value="23" lower_limit="-18" upper_limit="64"/>
                    <measurement group_id="O7" value="10" lower_limit="-29" upper_limit="50"/>
                    <measurement group_id="O8" value="156" lower_limit="116" upper_limit="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1</title>
        <description>Peak change from baseline in FEV1 (defined as the change at the highest value of FEV1 post-dose minus the baseline)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1</title>
          <description>Peak change from baseline in FEV1 (defined as the change at the highest value of FEV1 post-dose minus the baseline)</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286" lower_limit="239" upper_limit="333"/>
                    <measurement group_id="O2" value="269" lower_limit="223" upper_limit="316"/>
                    <measurement group_id="O3" value="266" lower_limit="220" upper_limit="313"/>
                    <measurement group_id="O4" value="235" lower_limit="189" upper_limit="282"/>
                    <measurement group_id="O5" value="225" lower_limit="178" upper_limit="273"/>
                    <measurement group_id="O6" value="166" lower_limit="118" upper_limit="214"/>
                    <measurement group_id="O7" value="114" lower_limit="67" upper_limit="161"/>
                    <measurement group_id="O8" value="366" lower_limit="318" upper_limit="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough Inspiratory Capacity (IC)</title>
        <description>Change from baseline in morning pre-dose trough IC (average of the 60 and 30-minute pre-dose assessments minus the baseline)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough Inspiratory Capacity (IC)</title>
          <description>Change from baseline in morning pre-dose trough IC (average of the 60 and 30-minute pre-dose assessments minus the baseline)</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" lower_limit="75" upper_limit="198"/>
                    <measurement group_id="O2" value="57" lower_limit="-4" upper_limit="118"/>
                    <measurement group_id="O3" value="101" lower_limit="40" upper_limit="162"/>
                    <measurement group_id="O4" value="142" lower_limit="81" upper_limit="203"/>
                    <measurement group_id="O5" value="73" lower_limit="10" upper_limit="137"/>
                    <measurement group_id="O6" value="54" lower_limit="-10" upper_limit="118"/>
                    <measurement group_id="O7" value="62" lower_limit="1" upper_limit="124"/>
                    <measurement group_id="O8" value="184" lower_limit="121" upper_limit="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC</title>
        <description>Peak change from baseline in IC (mean of 1 hr and 2 hr post-dose assessments)</description>
        <time_frame>Day 7 (mean of 1 hr and 2 hr post-dose assessments)</time_frame>
        <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC</title>
          <description>Peak change from baseline in IC (mean of 1 hr and 2 hr post-dose assessments)</description>
          <population>MITT Population: Subjects who completed at least 2 treatment periods with minimally 2 hours post-dosing on Day 14 for each of the treatment periods.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" lower_limit="227" upper_limit="377"/>
                    <measurement group_id="O2" value="234" lower_limit="160" upper_limit="309"/>
                    <measurement group_id="O3" value="254" lower_limit="180" upper_limit="328"/>
                    <measurement group_id="O4" value="312" lower_limit="238" upper_limit="386"/>
                    <measurement group_id="O5" value="195" lower_limit="118" upper_limit="272"/>
                    <measurement group_id="O6" value="159" lower_limit="82" upper_limit="236"/>
                    <measurement group_id="O7" value="99" lower_limit="24" upper_limit="174"/>
                    <measurement group_id="O8" value="390" lower_limit="314" upper_limit="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Morning Pre-dose Daily PEFR</title>
        <description>Change from baseline in mean morning pre-dose daily PEFR (peak expiratory flow rate) taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (excluding reading taken pre-dose on Visit 2 [Treatment Day 1])</description>
        <time_frame>Day 7 (60 minutes pre-dose, 30 minutes pre-dose)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Morning Pre-dose Daily PEFR</title>
          <description>Change from baseline in mean morning pre-dose daily PEFR (peak expiratory flow rate) taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (excluding reading taken pre-dose on Visit 2 [Treatment Day 1])</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.1" upper_limit="15.0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="-3.7" upper_limit="10.2"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-6.7" upper_limit="7.1"/>
                    <measurement group_id="O4" value="2.4" lower_limit="-4.5" upper_limit="9.3"/>
                    <measurement group_id="O5" value="-2.4" lower_limit="-9.5" upper_limit="4.6"/>
                    <measurement group_id="O6" value="-2.5" lower_limit="-9.5" upper_limit="4.6"/>
                    <measurement group_id="O7" value="-7.2" lower_limit="-14.1" upper_limit="-0.3"/>
                    <measurement group_id="O8" value="12.7" lower_limit="5.6" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Post-dose Daily PEFR</title>
        <description>Change from baseline in morning post-dose daily PEFR (peak expiratory flow rate) taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (excluding reading taken pre-dose on Visit 2 [Treatment Day 1])</description>
        <time_frame>Day 7 (30 minutes post-dose)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Post-dose Daily PEFR</title>
          <description>Change from baseline in morning post-dose daily PEFR (peak expiratory flow rate) taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (excluding reading taken pre-dose on Visit 2 [Treatment Day 1])</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="24.8" upper_limit="39.8"/>
                    <measurement group_id="O2" value="23.9" lower_limit="16.5" upper_limit="31.4"/>
                    <measurement group_id="O3" value="17.2" lower_limit="9.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="18.3" lower_limit="10.8" upper_limit="25.7"/>
                    <measurement group_id="O5" value="14.3" lower_limit="6.6" upper_limit="21.9"/>
                    <measurement group_id="O6" value="13.7" lower_limit="6.0" upper_limit="21.3"/>
                    <measurement group_id="O7" value="4.5" lower_limit="-2.9" upper_limit="12.0"/>
                    <measurement group_id="O8" value="38.0" lower_limit="30.4" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Evening Pre-dose PEFR</title>
        <description>Change from baseline in mean evening pre-dose daily peak flow readings taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (subjects taking Spiriva performed a single evening assessment)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Evening Pre-dose PEFR</title>
          <description>Change from baseline in mean evening pre-dose daily peak flow readings taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (subjects taking Spiriva performed a single evening assessment)</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="8.6" upper_limit="22.9"/>
                    <measurement group_id="O2" value="12.6" lower_limit="5.6" upper_limit="19.6"/>
                    <measurement group_id="O3" value="4.7" lower_limit="-2.3" upper_limit="11.7"/>
                    <measurement group_id="O4" value="11.2" lower_limit="4.2" upper_limit="18.3"/>
                    <measurement group_id="O5" value="7.5" lower_limit="0.2" upper_limit="14.7"/>
                    <measurement group_id="O6" value="5.9" lower_limit="-1.3" upper_limit="13.1"/>
                    <measurement group_id="O7" value="3.3" lower_limit="-3.8" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Evening Post-dose PEFR</title>
        <description>Change from baseline in mean evening post-dose daily peak flow readings taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (subjects taking Spiriva performed a single evening assessment)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 18 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Evening Post-dose PEFR</title>
          <description>Change from baseline in mean evening post-dose daily peak flow readings taken by subjects and recorded in subject diaries, up through Diary Day 7 of each treatment period (subjects taking Spiriva performed a single evening assessment)</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="34.2" upper_limit="50.2"/>
                    <measurement group_id="O2" value="30.3" lower_limit="22.4" upper_limit="38.3"/>
                    <measurement group_id="O3" value="21.6" lower_limit="13.7" upper_limit="29.5"/>
                    <measurement group_id="O4" value="24.3" lower_limit="16.3" upper_limit="32.3"/>
                    <measurement group_id="O5" value="20.2" lower_limit="12.1" upper_limit="28.3"/>
                    <measurement group_id="O6" value="22.1" lower_limit="14.0" upper_limit="30.2"/>
                    <measurement group_id="O7" value="11.0" lower_limit="3.1" upper_limit="19.0"/>
                    <measurement group_id="O8" value="35.6" lower_limit="27.4" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication</title>
        <description>Mean number of puffs of rescue medication recorded in subject diaries during each treatment period and by treatment and numbers of days treated</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication</title>
          <description>Mean number of puffs of rescue medication recorded in subject diaries during each treatment period and by treatment and numbers of days treated</description>
          <population>MITT Population</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.60" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.88" upper_limit="1.89"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.85" upper_limit="1.71"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.82" upper_limit="1.58"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1.03" upper_limit="1.99"/>
                    <measurement group_id="O6" value="1.6" lower_limit="1.12" upper_limit="2.19"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.46" upper_limit="2.66"/>
                    <measurement group_id="O8" value="0.9" lower_limit="0.63" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
        <description>Change from baseline in morning pre-dose trough FEV1 (average of the 60 and 30-minute pre-dose values on Treatment Day 14 minus the baseline)</description>
        <time_frame>Day 14 (average of the 60 and 30-minute pre-dose values on Treatment Day 14 minus the baseline)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
          <description>Change from baseline in morning pre-dose trough FEV1 (average of the 60 and 30-minute pre-dose values on Treatment Day 14 minus the baseline)</description>
          <population>MITT Population</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="47" upper_limit="132"/>
                    <measurement group_id="O2" value="80" lower_limit="38" upper_limit="122"/>
                    <measurement group_id="O3" value="67" lower_limit="26" upper_limit="109"/>
                    <measurement group_id="O4" value="77" lower_limit="35" upper_limit="118"/>
                    <measurement group_id="O5" value="68" lower_limit="25" upper_limit="111"/>
                    <measurement group_id="O6" value="29" lower_limit="-14" upper_limit="72"/>
                    <measurement group_id="O7" value="-8" lower_limit="-50" upper_limit="35"/>
                    <measurement group_id="O8" value="126" lower_limit="84" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1</title>
        <description>Peak change from baseline in FEV1 (defined as the change at the highest value of FEV1 post-dose minus the baseline)</description>
        <time_frame>Day 14</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1</title>
          <description>Peak change from baseline in FEV1 (defined as the change at the highest value of FEV1 post-dose minus the baseline)</description>
          <population>MITT Population</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="54"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" lower_limit="236" upper_limit="339"/>
                    <measurement group_id="O2" value="288" lower_limit="237" upper_limit="340"/>
                    <measurement group_id="O3" value="287" lower_limit="236" upper_limit="338"/>
                    <measurement group_id="O4" value="261" lower_limit="210" upper_limit="312"/>
                    <measurement group_id="O5" value="246" lower_limit="193" upper_limit="299"/>
                    <measurement group_id="O6" value="188" lower_limit="135" upper_limit="241"/>
                    <measurement group_id="O7" value="130" lower_limit="77" upper_limit="183"/>
                    <measurement group_id="O8" value="361" lower_limit="309" upper_limit="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Mean Morning Pre-dose Trough IC</title>
        <description>Change from baseline for mean morning pre-dose trough IC (average of the 60 and 30-minute pre-dose assessments minus the baseline)</description>
        <time_frame>Day 14 (average of the 60 and 30-minute pre-dose assessments minus the baseline)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Mean Morning Pre-dose Trough IC</title>
          <description>Change from baseline for mean morning pre-dose trough IC (average of the 60 and 30-minute pre-dose assessments minus the baseline)</description>
          <population>MITT Population</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="32" upper_limit="156"/>
                    <measurement group_id="O2" value="45" lower_limit="-16" upper_limit="106"/>
                    <measurement group_id="O3" value="64" lower_limit="3" upper_limit="124"/>
                    <measurement group_id="O4" value="104" lower_limit="43" upper_limit="165"/>
                    <measurement group_id="O5" value="69" lower_limit="6" upper_limit="132"/>
                    <measurement group_id="O6" value="34" lower_limit="-30" upper_limit="97"/>
                    <measurement group_id="O7" value="9" lower_limit="-54" upper_limit="71"/>
                    <measurement group_id="O8" value="138" lower_limit="76" upper_limit="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC</title>
        <description>Peak change from baseline in IC (mean of 1 and 2 hour post-dose assessments minus the baseline)</description>
        <time_frame>Day 14 (mean of 1 and 2 hour post-dose assessments minus the baseline)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC</title>
          <description>Peak change from baseline in IC (mean of 1 and 2 hour post-dose assessments minus the baseline)</description>
          <population>MITT Population</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280" lower_limit="197" upper_limit="363"/>
                    <measurement group_id="O2" value="259" lower_limit="177" upper_limit="341"/>
                    <measurement group_id="O3" value="288" lower_limit="206" upper_limit="370"/>
                    <measurement group_id="O4" value="226" lower_limit="145" upper_limit="308"/>
                    <measurement group_id="O5" value="261" lower_limit="176" upper_limit="346"/>
                    <measurement group_id="O6" value="172" lower_limit="87" upper_limit="256"/>
                    <measurement group_id="O7" value="77" lower_limit="-6" upper_limit="161"/>
                    <measurement group_id="O8" value="284" lower_limit="200" upper_limit="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12-hour Post-dose Trough FEV1</title>
        <description>12-hour post-dose trough FEV1 was defined as the mean of the FEV1 assessments taken at 11.5 and 12 hours post-dose minus the baseline</description>
        <time_frame>Day 14 (Baseline, 11.5 and 12 hours post dose)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12-hour Post-dose Trough FEV1</title>
          <description>12-hour post-dose trough FEV1 was defined as the mean of the FEV1 assessments taken at 11.5 and 12 hours post-dose minus the baseline</description>
          <population>MITT Population</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="54"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="69" upper_limit="163"/>
                    <measurement group_id="O2" value="69" lower_limit="22" upper_limit="117"/>
                    <measurement group_id="O3" value="99" lower_limit="52" upper_limit="145"/>
                    <measurement group_id="O4" value="112" lower_limit="65" upper_limit="158"/>
                    <measurement group_id="O5" value="66" lower_limit="17" upper_limit="115"/>
                    <measurement group_id="O6" value="55" lower_limit="7" upper_limit="104"/>
                    <measurement group_id="O7" value="1" lower_limit="-48" upper_limit="49"/>
                    <measurement group_id="O8" value="164" lower_limit="116" upper_limit="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Morning Pre-dose Daily PEFR</title>
        <description>Change from baseline in mean morning pre-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (mean reading excluded reading taken pre-dose on Visit 2 [Treatment 1 Day 1]</description>
        <time_frame>Baseline, Treatment Day 1 and every day, to the end of the 14-Day Treatment period before dosing, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Morning Pre-dose Daily PEFR</title>
          <description>Change from baseline in mean morning pre-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (mean reading excluded reading taken pre-dose on Visit 2 [Treatment 1 Day 1]</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="2.1" upper_limit="15.1"/>
                    <measurement group_id="O2" value="6.2" lower_limit="-0.3" upper_limit="12.8"/>
                    <measurement group_id="O3" value="2.0" lower_limit="-4.5" upper_limit="8.5"/>
                    <measurement group_id="O4" value="4.4" lower_limit="-2.1" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0.3" lower_limit="-6.4" upper_limit="6.9"/>
                    <measurement group_id="O6" value="-0.5" lower_limit="-7.1" upper_limit="6.2"/>
                    <measurement group_id="O7" value="-6.3" lower_limit="-12.7" upper_limit="0.2"/>
                    <measurement group_id="O8" value="14.8" lower_limit="8.2" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Morning Post-dose Daily PEFR</title>
        <description>Change from baseline in mean morning post-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (mean reading excluded reading taken pre-dose on Visit 2 [Treatment 1 Day 1]</description>
        <time_frame>Baseline, Treatment Day 1 and every day, to the end of the 14-Day Treatment period 30 minutes post dosing, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Morning Post-dose Daily PEFR</title>
          <description>Change from baseline in mean morning post-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (mean reading excluded reading taken pre-dose on Visit 2 [Treatment 1 Day 1]</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="25.8" upper_limit="40.4"/>
                    <measurement group_id="O2" value="26.7" lower_limit="19.4" upper_limit="33.9"/>
                    <measurement group_id="O3" value="20.2" lower_limit="13.0" upper_limit="27.4"/>
                    <measurement group_id="O4" value="20.3" lower_limit="13.1" upper_limit="27.5"/>
                    <measurement group_id="O5" value="14.8" lower_limit="7.5" upper_limit="22.2"/>
                    <measurement group_id="O6" value="14.3" lower_limit="6.9" upper_limit="21.7"/>
                    <measurement group_id="O7" value="5.3" lower_limit="-1.9" upper_limit="12.5"/>
                    <measurement group_id="O8" value="39.8" lower_limit="32.5" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Evening Pre-dose Daily PEFR</title>
        <description>Change from baseline in mean evening pre-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (subjects taking Spiriva performed a single evening assessment)</description>
        <time_frame>Treatment Day 1 to the end of the 14-Day Treatment, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Evening Pre-dose Daily PEFR</title>
          <description>Change from baseline in mean evening pre-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (subjects taking Spiriva performed a single evening assessment)</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="8.8" upper_limit="22.5"/>
                    <measurement group_id="O2" value="14.9" lower_limit="8.1" upper_limit="21.7"/>
                    <measurement group_id="O3" value="7.2" lower_limit="0.5" upper_limit="13.9"/>
                    <measurement group_id="O4" value="11.7" lower_limit="4.9" upper_limit="18.5"/>
                    <measurement group_id="O5" value="5.0" lower_limit="-1.9" upper_limit="12.0"/>
                    <measurement group_id="O6" value="6.9" lower_limit="-0.0" upper_limit="13.8"/>
                    <measurement group_id="O7" value="5.7" lower_limit="-1.1" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Evening Post-dose Daily PEFR</title>
        <description>Change from baseline in mean evening post-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (subjects taking Spiriva performed a single evening assessment)</description>
        <time_frame>Through the end of the 14-Day Treatment</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Evening Post-dose Daily PEFR</title>
          <description>Change from baseline in mean evening post-dose daily peak flow readings taken by subjects and recorded in subject diaries during each treatment period for subjects with more than 7 days of diary data (subjects taking Spiriva performed a single evening assessment)</description>
          <population>MITT Population</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" lower_limit="33.6" upper_limit="49.2"/>
                    <measurement group_id="O2" value="32.7" lower_limit="24.9" upper_limit="40.5"/>
                    <measurement group_id="O3" value="24.7" lower_limit="16.9" upper_limit="32.4"/>
                    <measurement group_id="O4" value="27.0" lower_limit="19.3" upper_limit="34.8"/>
                    <measurement group_id="O5" value="19.4" lower_limit="11.5" upper_limit="27.3"/>
                    <measurement group_id="O6" value="22.7" lower_limit="14.8" upper_limit="30.6"/>
                    <measurement group_id="O7" value="13.5" lower_limit="5.8" upper_limit="21.3"/>
                    <measurement group_id="O8" value="35.9" lower_limit="28.1" upper_limit="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication (End of Treatment)</title>
        <description>Mean number of puffs of rescue medication recorded in subject diaries during each treatment period and by treatment and numbers of days treated</description>
        <time_frame>Day 14 (End of treatment)</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication (End of Treatment)</title>
          <description>Mean number of puffs of rescue medication recorded in subject diaries during each treatment period and by treatment and numbers of days treated</description>
          <population>MITT Population</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="68"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.56" upper_limit="1.28"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.83" upper_limit="1.81"/>
                    <measurement group_id="O3" value="1.19" lower_limit="0.83" upper_limit="1.66"/>
                    <measurement group_id="O4" value="1.11" lower_limit="0.79" upper_limit="1.51"/>
                    <measurement group_id="O5" value="1.43" lower_limit="1.02" upper_limit="1.95"/>
                    <measurement group_id="O6" value="1.57" lower_limit="1.12" upper_limit="2.15"/>
                    <measurement group_id="O7" value="1.92" lower_limit="1.39" upper_limit="2.56"/>
                    <measurement group_id="O8" value="0.87" lower_limit="0.60" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 (mL) Averaging Treatment Day 7 and Day 14</title>
        <description>Change from Baseline in Morning Pre-dose Trough FEV1 (mL) Averaging Treatment Day 7 and Day 14</description>
        <time_frame>Day 1 through Day 14</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 µg BID</title>
            <description>GP MDI 18 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 9 µg BID</title>
            <description>GP MDI 9 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 4.6 µg BID</title>
            <description>GP MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 2.4 µg BID</title>
            <description>GP MDI 2.4 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.2 µg BID</title>
            <description>GP MDI 1.2 µg BID.</description>
          </group>
          <group group_id="O6">
            <title>GP MDI 0.6 µg BID</title>
            <description>GP MDI 0.6 µg BID.</description>
          </group>
          <group group_id="O7">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O8">
            <title>Spiriva® Handihaler®</title>
            <description>Spiriva® Handihaler® (Tiotropium Bromide).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 (mL) Averaging Treatment Day 7 and Day 14</title>
          <description>Change from Baseline in Morning Pre-dose Trough FEV1 (mL) Averaging Treatment Day 7 and Day 14</description>
          <population>MITT Population</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" lower_limit="0.053" upper_limit="0.123"/>
                    <measurement group_id="O2" value="0.087" lower_limit="0.052" upper_limit="0.121"/>
                    <measurement group_id="O3" value="0.090" lower_limit="0.056" upper_limit="0.124"/>
                    <measurement group_id="O4" value="0.086" lower_limit="0.052" upper_limit="0.120"/>
                    <measurement group_id="O5" value="0.056" lower_limit="0.021" upper_limit="0.091"/>
                    <measurement group_id="O6" value="0.023" lower_limit="-0.013" upper_limit="0.058"/>
                    <measurement group_id="O7" value="0.001" lower_limit="-0.034" upper_limit="0.036"/>
                    <measurement group_id="O8" value="0.141" lower_limit="0.107" upper_limit="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All of the adverse events (AEs) reported during the study were captured after signing informed consent through the 7-14 day follow up period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GP MDI 18 µg BID</title>
          <description>GP MDI 18 µg BID.</description>
        </group>
        <group group_id="E2">
          <title>GP MDI 9 µg BID</title>
          <description>GP MDI 9 µg BID.</description>
        </group>
        <group group_id="E3">
          <title>GP MDI 4.6 µg BID</title>
          <description>GP MDI 4.6 µg BID.</description>
        </group>
        <group group_id="E4">
          <title>GP MDI 2.4 µg BID</title>
          <description>GP MDI 2.4 µg BID.</description>
        </group>
        <group group_id="E5">
          <title>GP MDI 1.2 µg BID</title>
          <description>GP MDI 1.2 µg BID.</description>
        </group>
        <group group_id="E6">
          <title>GP MDI 0.6 µg BID</title>
          <description>GP MDI 0.6 µg BID.</description>
        </group>
        <group group_id="E7">
          <title>Placebo MDI</title>
          <description>Placebo MDI.</description>
        </group>
        <group group_id="E8">
          <title>Spiriva 18 µg</title>
          <description>Spiriva 18 µg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics Inc</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

